Tango Therapeutics, Inc.
TNGX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $565,969 | $151,113 | $335,833 |
| - Cash | $58,338 | $39,700 | $58,432 | $69,530 |
| + Debt | $31,661 | $35,008 | $36,946 | $36,493 |
| Enterprise Value | – | $561,277 | $129,627 | $302,796 |
| Revenue | $53,811 | $3,181 | $5,392 | $4,117 |
| % Growth | 1,591.6% | -41% | 31% | – |
| Gross Profit | $53,256 | $2,556 | $5,392 | $4,117 |
| % Margin | 99% | 80.4% | 100% | 100% |
| EBITDA | $16,429 | -$38,193 | -$41,908 | -$40,290 |
| % Margin | 30.5% | -1,200.7% | -777.2% | -978.6% |
| Net Income | $15,884 | -$38,853 | -$39,876 | -$37,670 |
| % Margin | 29.5% | -1,221.4% | -739.5% | -915% |
| EPS Diluted | 0.143 | -0.35 | -0.36 | -0.34 |
| % Growth | 140.9% | 2.8% | -5.9% | – |
| Operating Cash Flow | -$30,952 | -$36,519 | -$41,697 | -$36,647 |
| Capital Expenditures | -$151 | -$624 | -$51 | -$124 |
| Free Cash Flow | -$31,103 | -$37,143 | -$41,748 | -$36,771 |